Oxford Classic – a novel prognostic signature to guide treatment decisions in ovarian cancer

Applications: Pre-treatment risk stratification; Precision medicine; ovarian cancer stratification

The Oxford Classic is a thoroughly validated prognostic tool that identifies ‘EMT-high’ tumours that have a particularly poor prognosis associated with an aggressive disease in High Grade Serous Ovarian cancer (HGSOC). Pre-treatment risk stratification of patients using the Oxford Classic can suggest [i] the most suitable surgical strategy for patients, and [ii] the most suitable EMT-targeting therapies for patients.

Features	Benefits
A molecular signature that can robustly identify HGSOC patients with poor prognosis (70% of patients) as validated in 14 independent cohorts of patients.	Oxford Classic-based risk stratification of patients can guide treatment decisions including surgical strategy and targeted therapies, which can significantly improve survival rates in HGSOC.
Oxford Classic captures tumour heterogeneity by identifying five phenotypic cell types, ie; EMT cells, Cell cycle, Differentiated, KRT17 and Ciliated cells.	Provides a comprehensive molecular profile of the tumour, improving prognostic accuracy and enabling more nuanced patient stratification.
Potential for use in stratifying patients for promising cancer therapies.	Patients can avoid painful, unnecessary surgeries once prognosis is detected by Oxford Classic Identifies patients eligible for early inclusion in clinical trials targeting EMT.

Patented and available for:

Licensing
Co-development
Consulting

Request more information
about this technology

Back to Technologies Available

Technologies for License

Oxford Classic – a novel prognostic signature to guide treatment decisions in ovarian cancer

Ready to get in touch?